Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTN2JFW)

• DTT Name: T-cell surface glycoprotein CD4 (CD4) DTT Info
• Gene Name: CD4

Molecule-Related Drug & Molecule List

1 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibalizumab	DMV67QO	Human immunodeficiency virus infection	1C62	Approved	[1]

10 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Magrolimab	DMVXUR0	Acute myeloid leukaemia	2A60	Phase 3	[2]
TNX-355	DMYA41S	Human immunodeficiency virus infection	1C62	Phase 3	[3]
Zanolimumab	DMKB4ZY	Lymphoma	2A80-2A86	Phase 3	[4]
BT-061	DM2LZIY	Asthma	CA23	Phase 2	[5]
Fluoropeptide vaccine	DMCEUOH	Influenza virus infection	1E30-1E32	Phase 2	[6]
CD4CAR	DM09SW6	T-cell leukaemia	2A90	Phase 1	[7]
Combinectin	DMTLP1N	Human immunodeficiency virus infection	1C62	Phase 1	[8]
LIPO-4	DMJRALD	Human immunodeficiency virus infection	1C62	Phase 1	[9]
TMB-365	DMH3E5C	Human immunodeficiency virus-1 infection	1C62	Phase 1	[10]
VRC07-523LS	DM0S9OT	Human immunodeficiency virus-1 infection	1C62	Phase 1	[11]

1 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IDEC-151	DMILUHA	Rheumatoid arthritis	FA20	Discontinued in Phase 2	[12]

1 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CEL-1000	DMRYX1P	Solid tumour/cancer	2A00-2F9Z	Investigative	[13]

References

• [1] 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
• [2] Current and emerging strategies for management of myelodysplastic syndromes. Blood Rev. 2021 Jul;48:100791.
• [3] Progress in targeting HIV-1 entry. Drug Discov Today. 2005 Aug 15;10(16):1085-94.
• [4] Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007 Jun 1;109(11):4655-62.
• [5] Tregalizumab (BT-061) increases regulatory T cell function. Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061). Immunol Cell Biol.2015 Apr;93(4):321-2.
• [6] A novel peptide-based pan-influenza A vaccine: a double blind, randomised clinical trial of immunogenicity and safety. Vaccine. 2015 Jan 3;33(2):396-402.
• [7] Clinical pipeline report, company report or official report of iCell Gene Therapeutics.
• [8] Clinical pipeline report, company report or official report of ViiV Healthcare.
• [9] Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16). Vaccine. 2013 Sep 13;31(40):4406-15.
• [10] Clinical pipeline report, company report or official report of TaiMed Biologics.
• [11] Clinical pipeline report, company report or official report of TaiMed Biologics.
• [12] Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41.
• [13] A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner. Antimicrob Agents Chemother. 2004 Jul;48(7):2455-63.